Clinical Trial Update: A Dose-finding Phase IIb Study With AZD0865 and Esomeprazole in GERD Patients Without Erosive Esophagitis. [Phase 2]

View source ↗

Summary

A completed Phase IIb dose-finding trial evaluated AZD0865 in combination with esomeprazole for gastroesophageal reflux disease without erosive esophagitis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroesophageal Reflux Disease

Drugs mentioned

• AZD0865
• Esomeprazole (Esomeprazole)

Snippet

Sponsor: AstraZeneca | Conditions: GERD Without Erosive Esophagitis | Phase 2 | Status: COMPLETED